Berberine can amplify cytotoxic effect of radiotherapy by targeting cancer stem cells

IF 0.4 Q4 ONCOLOGY

Breast Cancer Management Pub Date : 2020-06-01 DOI:10.2217/bmt-2020-0007

Sanaa A. El-Benhawy, Heba G. El-Sheredy, H. Ghanem, A. A. Abo El-Soud

{"title":"Berberine can amplify cytotoxic effect of radiotherapy by targeting cancer stem cells","authors":"Sanaa A. El-Benhawy, Heba G. El-Sheredy, H. Ghanem, A. A. Abo El-Soud","doi":"10.2217/bmt-2020-0007","DOIUrl":null,"url":null,"abstract":"Aim: Our objective was to investigate the effect of ionizing radiation (IR) and berberine on the expression of stem cell markers OCT4 and SOX2. Materials & methods: The study involved the following groups: Group I: MCF-7 spheroids as untreated control; Group II: MCF-7 spheroids treated with IR; Group III: MCF-7 spheroids treated with berberine; and Group IV: MCF-7 spheroids treated with berberine + IR. MCF-7 spheroids’ metabolic activity and viability was determined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. OCT4 and SOX2 genes expression were assayed by real time-plymerase chain reaction (RT-PCR). Results: IR and berberine treatment decreased the viability of MCF-7 spheroids and reduced OCT4 and SOX2 genes expression. Combining berberine with IR leads to a significant reduction in cell viability and OCT4 and SOX2 genes expression when compared with radiation alone treated group. Conclusion: Berberine showed to be a good candidate for further studies as a new anticancer drug in the treatment of breast cancer. Berberine has a radiosensitizing effect through targeting cancer stem cells.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/bmt-2020-0007","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/bmt-2020-0007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Aim: Our objective was to investigate the effect of ionizing radiation (IR) and berberine on the expression of stem cell markers OCT4 and SOX2. Materials & methods: The study involved the following groups: Group I: MCF-7 spheroids as untreated control; Group II: MCF-7 spheroids treated with IR; Group III: MCF-7 spheroids treated with berberine; and Group IV: MCF-7 spheroids treated with berberine + IR. MCF-7 spheroids’ metabolic activity and viability was determined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. OCT4 and SOX2 genes expression were assayed by real time-plymerase chain reaction (RT-PCR). Results: IR and berberine treatment decreased the viability of MCF-7 spheroids and reduced OCT4 and SOX2 genes expression. Combining berberine with IR leads to a significant reduction in cell viability and OCT4 and SOX2 genes expression when compared with radiation alone treated group. Conclusion: Berberine showed to be a good candidate for further studies as a new anticancer drug in the treatment of breast cancer. Berberine has a radiosensitizing effect through targeting cancer stem cells.

查看原文本刊更多论文

黄连素可通过靶向癌症干细胞增强放射治疗的细胞毒性作用

目的:研究电离辐射(IR)和黄连素对干细胞标志物OCT4和SOX2表达的影响。材料与方法:研究分为以下组:第一组:MCF-7球体作为未处理对照;II组:经IR处理的MCF-7球体;III组:用小檗碱治疗MCF-7球状体;IV组:用小檗碱+ IR治疗MCF-7球体。采用3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四氮唑法测定MCF-7球体的代谢活性和活力。采用实时聚合酶链反应(RT-PCR)检测OCT4和SOX2基因的表达。结果:IR和小檗碱处理可降低MCF-7球体的活力，降低OCT4和SOX2基因的表达。与单独放疗组相比，小檗碱与IR联合治疗导致细胞活力和OCT4和SOX2基因表达显著降低。结论:小檗碱作为一种新型抗癌药物在治疗乳腺癌方面具有良好的研究前景。小檗碱通过靶向癌症干细胞具有放射增敏作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer Management ONCOLOGY-

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Breast Cancer Management (ISSN: 1758-1923) addresses key issues in disease management by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Breast Cancer Management provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances clinical practice in the field are reported and analyzed by international experts. The journal presents this information in clear, accessible formats. All articles are subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3. Coverage includes: Diagnosis and imaging, Surgical approaches, Radiotherapy, Systemic therapies, Cancer clinical trials, Genetic aspects of disease, Personalized medicine, Translational research and biomarker studies, Management of psychological distress, Epidemiological studies, Pharmacoeconomics, Evidence-based treatment guidelines.